Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

666
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
666
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.0K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.0K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

716
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
716
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

986
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
986

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-dose and very low-dose glucocorticoids: which low is low risk? - Authors' reply.

The Lancet. Rheumatology·2026
Same author

Executive Summary: The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.

Rheumatology (Oxford, England)·2026
Same author

The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.

Rheumatology (Oxford, England)·2026
Same author

The role of antimicrobial peptides in rheumatoid arthritis: From mucosal predisposition to chronic synovitis.

Autoimmunity reviews·2026
Same author

Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series.

Annals of the rheumatic diseases·2026
Same author

A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection.

The Journal of antimicrobial chemotherapy·2026

Related Experiment Video

Updated: Apr 14, 2026

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
08:02

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

Published on: April 25, 2016

10.2K

Novel glucocorticoids: current status and challenges.

Frank Buttgereit1, Christopher J Edwards2

  • 1Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, and Deutsches Rheumaforschungszentrum, ein Institut der Leibniz Gemeinschaft, Berlin, Germany.

Rheumatology (Oxford, England)
|April 12, 2026
PubMed
Summary
This summary is machine-generated.

New strategies aim to reduce the harm from glucocorticoids in inflammatory diseases. Research explores selective agonists, targeted delivery, and combination therapies to minimize steroid toxicity.

Keywords:
11β-HSD1 inhibitioncombination therapyglucocorticoid toxicityglucocorticoid-sparing strategiesselective glucocorticoid receptor agonists and modulatorstargeted drug delivery

More Related Videos

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System
13:22

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System

Published on: September 10, 2013

12.6K
Biochemical Reconstitution of Steroid Receptor•Hsp90 Protein Complexes and Reactivation of Ligand Binding
11:07

Biochemical Reconstitution of Steroid Receptor•Hsp90 Protein Complexes and Reactivation of Ligand Binding

Published on: September 21, 2011

17.0K

Related Experiment Videos

Last Updated: Apr 14, 2026

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
08:02

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

Published on: April 25, 2016

10.2K
A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System
13:22

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System

Published on: September 10, 2013

12.6K
Biochemical Reconstitution of Steroid Receptor•Hsp90 Protein Complexes and Reactivation of Ligand Binding
11:07

Biochemical Reconstitution of Steroid Receptor•Hsp90 Protein Complexes and Reactivation of Ligand Binding

Published on: September 21, 2011

17.0K

Area of Science:

  • Rheumatology
  • Pharmacology
  • Immunology

Background:

  • Glucocorticoids are essential but toxic treatments for inflammatory diseases.
  • Reducing glucocorticoid toxicity is a major clinical challenge.
  • Current treatments often involve a trade-off between efficacy and adverse effects.

Purpose of the Study:

  • To review novel approaches for reducing glucocorticoid toxicity in rheumatology.
  • To discuss strategies for optimizing glucocorticoid use and developing alternatives.
  • To highlight the importance of documenting glucocorticoid-induced toxicity.

Main Methods:

  • Review of current research on novel glucocorticoid receptor (GR) ligands.
  • Analysis of selective GR agonists and modulators (SEGRAMs).
  • Examination of targeted delivery systems and combination therapies (e.g., prednisone with 11beta-HSD-1 inhibitors).

Main Results:

  • Development of SEGRAMs and targeted delivery methods show promise.
  • Combination therapies offer potential for reduced glucocorticoid dosage.
  • Optimizing glucocorticoid use requires careful benefit-risk assessment.

Conclusions:

  • Novel therapeutic strategies are emerging to mitigate glucocorticoid toxicity.
  • Glucocorticoid-sparing approaches are crucial for managing inflammatory diseases.
  • Continued research and documentation are vital for developing safer alternatives.